For clinical progress to occur in lung cancer, advances must be made in many inter-related areas. Advances in chemoprevention will be most useful if testing is able to identify those at greatest risk of developing lung cancer. Advances in surgical and ablative therapies will be most useful if testing is able to identify lung cancer at the earliest possible stage. Advances in systemic, targeted and individualised therapies will be most useful if testing is able to predict the nature of a patient's lung cancer and the response to specific treatment choices.
A new test can improve on currently used tests by being more accurate, less invasive, less expensive and/or novel in its intent. To have a clinical impact, the result of the test must affect a decision to the benefit of the patient. The most recently developed tests that have had this sort of impact in lung cancer are positron emission tomographic imaging, 1 advances in diagnostic bronchoscopy (electromagnetic navigation, 2 endobronchial ultrasound 3 ) and perhaps epidermal growth factor receptor analysis. 4 Progress is occurring on many fronts in lung cancer testing. The clinical impact of imaging advances such as dual energy imaging, 5 temporal subtraction, 6 computer-aided detection/diagnosis 7 and volumetric analysis 8 of lung nodules is being assessed. Bronchoscopic advances in the use of ultrathin bronchoscopes, 9 navigation programmes, 2 ultrasound-guided sampling procedures, 3 narrow band imaging 10 and optical coherence tomography 11 are occurring. We have seen advances in molecular testing through the analysis of tumour and airway tissue genomes 12 13 and proteomes, 14 as well as blood proteomes, 15 DNA methylation, 16 circulating tumour cells, 17 antibodies to tumourassociated antigens 18 and microRNA profiles. 19 Finally, there is hope that analysis of the volatile and non-volatile 20 components of exhaled breath will provide useful information about our patients.
In this issue of Thorax, progress on the testing of exhaled breath volatile compounds as a diagnostic in lung cancer is presented. Volatile organic compounds (VOCs) are present in the breath in very low concentrations (parts per billion to parts per trillion volume). They can be inhaled into the lungs and absorbed through the skin from exogenous sources, or can be generated directly from the cellular biochemical processes of the body (eg, lipid peroxidation of fatty acid components of cell membranes). The origin of many endogenous VOCs is not known. Several lines of evidence suggest that the biochemical processes of lung cancer cells differ from those of normal cells. Thus, it is reasonable to expect that the pattern of exhaled volatile compounds in patients with lung cancer would be different from that of individuals without lung cancer.
The concept that a unique pattern of exhaled VOCs exists in those with lung cancer has been studied previously. Some researchers have evaluated gas chromatography/mass spectrometry (GC/MS) systems, while others have investigated the use of non-specific chemical sensing matrix devices for this purpose. There are benefits and downsides to the use of either of these technologies. GC/MS devices are able to identify the specific components of a gas mixture at low concentrations, but they are cumbersome to use and expensive. Chemical sensing matrix devices are easier to use as a point of care test and relatively inexpensive, but they do not identify the actual compounds and may lack enough sensitivity to various volatile compounds to be accurate. Despite these concerns, both techniques have shown promise with accuracies in the 70-85% range for the identification of lung cancer being reported. The studies have differed in the breath collection methods used, the populations tested and the statistical methods applied to identify the unique patterns as well as to validate the model developed. 21 Technological advances should lead to progress in breath testing. Chemical sensing devices have been developed that can detect VOCs at lower concentrations than traditional GC/MS in near real-time. In this issue of Thorax, Westhoff et al 22 describe the use of one such device for the analysis of exhaled breath (see page 744). This device, called an ion mobility spectrometer, is able to detect volatile compounds at a tenfold lower concentration than standard GC/MS devices in approximately one-fifth of the time. It does not, however, identify the specific compounds in the mixture. The authors enrolled subjects with lung cancer and healthy controls. They were able to demonstrate a complete separation of the breath signals between these groups. These results hold promise for this or similar devices to be developed into an accurate diagnostic tool, but should be viewed as pilot information only. The authors did not include control subjects with other medical problems, their control group was younger than the cancer group, most of the cancer subjects had relatively advanced disease and they did not use a separate validation cohort. All of these factors may influence the accuracy of the tested device in future studies.
The field of lung cancer test development is on the verge of some major advances. In the near future we may have testing available that will help us to assess the risk of developing lung cancer, diagnose lung cancer at an earlier stage, improve our ability to predict the course of lung cancer once diagnosed and intelligently individualise treatment decisions. These tests will foster advances in other areas of lung cancer management to the benefit of our patients.
The b 2 receptor and airway hyper-responsiveness: are sensory nerves involved?
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The use of b 2 agonists for the control of symptoms is central to the treatment of patients with asthma. However, there is controversy surrounding the regular use of this drug class as numerous studies have demonstrated a variety of changes that can be considered unwanted attributes, particularly when these drugs are used regularly as monotherapy. These include increased bronchial hyper-responsiveness (BHR) to inhaled contractile agents 1 and an increase in the allergeninduced early 2 and late asthmatic response 3 following regular treatment with short-acting b 2 agonists (SABAs). Furthermore, a number of studies have suggested that regular treatment with inhaled SABAs and long-acting b 2 agonists (LABAs) by inhalation leads to a loss of bronchoprotection 4 5 and with salmeterol treatment an excess mortality in patients with asthma, 6 a trend also observed with regular treatment with formoterol. 7 This has led the Food and Drug Administration (FDA) to post black-box warnings on all medicines containing these LABAs.
Christian Virchow and colleagues from Rostock have provided data (see page 763) on a potential mechanism as to how regular treatment with salmeterol can paradoxically increase BHR. 8 Eighteen patients with mild allergic asthma inhaled standard doses of salmeterol xinafoate for 2 weeks, followed by 2 weeks of treatment with the combination of fluticasone and salmeterol xinafoate. There was no overall statistically significant change in BHR for the whole group receiving monotherapy with salmeterol. However, 67% of the patients showed a modest increase in BHR as measured by a lowered PC 20 (provocative concentration of histamine causing a 20% fall in the forced expiratory volume in 1 s) following monotherapy with salmeterol compared with baseline. This contrasted with a statistically significant improvement in BHR following the combination therapy. The levels of brain-derived neurotrophic factor (BDNF) were elevated in both serum and platelets obtained from patients receiving monotherapy with salmeterol, and the changes in BDNF levels correlated with the changes in PC 20 , although the levels of BDNF decreased significantly and there was no such correlation with changes in PC 20 in the patients receiving the combination therapy. The changes in PC 20 following monotherapy with inhaled salmeterol did not show a correlation with known b 2 receptor polymorphisms.
A number of other investigators have suggested a role for BDNF in BHR as this is a mediator that is increased in subjects with asthma, both in the lung 9 and in platelets, 10 and which at least in animal models can induce BHR associated with changes in neuronal activity. 11 In patients with asthma, the systemic levels of BDNF are also elevated, whilst they correlate with BHR. 9 Increases in BDNF levels in the lung following allergen challenge of patients with asthma can be reduced by glucocorticosteroids. 12 Airway sensory nerves have also been implicated in the pathogenesis of BHR induced by a number of stimuli, 13 including treatment with regular b 2 agonists, 14 and it is of particular interest that platelet activation has also been observed to play a central role in allergen-induced BHR experimentally, 15 16 supporting the observations of Virchow and colleagues in the present study. Interestingly, salmeterol enhanced the secretion of BDNF from tumour necrosis factor a (TNFa)-stimulated human peripheral blood mononuclear cells, whilst BDNF secretion was inhibited by fluticasone.
Clearly it would be of interest to see if salmeterol also caused an increase in BDNF secretion from platelets, thus allowing a clearer link between platelet activation, BDNF and the exacerbation of BHR observed following monotherapy with regular inhaled salmeterol. Whilst the acute benefits of b 2 agonist therapy are well accepted, the worsening of asthma control with chronic b 2 agonist treatment is not as well accepted, with a recent study reinforcing the safety of regular b 2 agonists use. 17 Nonetheless, a number of mechanisms have been put forward to explain worsening asthma control with regular b 2 agonist treatment, including increased antigen burden, 18 increased BHR induced by the (+) enantiomer 14 and loss of bronchoprotection.
